Skip to main
  1. Stocks
  2. Innoviva
  3. Forecast
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Innoviva is attractive because its royalty base from Breo and Anoro provides durable, high-margin cash flow through 2030, with roughly $1.0B in expected royalty revenue over the next five years helping fund growth and shareholder returns. Its operating portfolio is also accelerating, as 2Q26 IST revenue rose 26% y/y to $36.6M, led by Giapreza and XacDuro, while internally marketed products exceeded $180M in LTM revenue as of March 2026 and grew 37% y/y in 1Q26. The company also has multiple value-creating catalysts from Nortiva Bio’s LYNX platform, strategic investments such as Armata, and a strong balance sheet with $603.1M in cash at 1Q26, supporting further capital deployment and repurchases.

Bears say

Innoviva is facing a weaker fundamental backdrop as royalty revenue came in at $59.8M, down 11% year over year, with GSK citing U.S. pricing pressure and softer inhaled respiratory demand, while FactSet consensus for 2026/2027 has already fallen about 6% to 7%. The company also has limited offset from newer products, as Zevtera sales were only about $0.4M, up 3.5% year over year, and expectations were cut materially from a prior peak of roughly $72M to about $39M in 2033E amid launch and clinical execution risk. In addition, Innoviva’s valuation is exposed to volatile strategic holdings, including a roughly 28% decline in Armata shares in 3Q26 that implies about a $45M loss plus $17M to $20M in warrant value, while ongoing competition and capital-allocation risk could further pressure future royalty growth and returns.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Innoviva (INVA) Analyst Forecast & Price Prediction

Get the latest Innoviva (INVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Innoviva (INVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Innoviva (INVA) Analyst Forecast & Price Prediction

Get the latest Innoviva (INVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Innoviva (INVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INVA stock data and trends